Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04785326 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Dong-A ST Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT04785326 is a Phase 3 study that has completed, run by Dong-A ST Co.. The registered enrollment target is 598 participants.
The verdict
NCT04785326, a Phase 3 study, has completed, sponsored by Dong-A ST Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
Interventions
- DRUG DMB-3115
- DRUG Stelara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04785326
The ClinicalTrials.gov registry entry for NCT04785326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dong-A ST Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DMB-3115 is the first listed.
NCT04785326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04785326 about?
NCT04785326 is a clinical study titled "Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis". This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT04785326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2021-04-28. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT04785326?
The interventions under investigation include: DMB-3115 (DRUG), Stelara (DRUG).
Who is sponsoring clinical trial NCT04785326?
This trial is sponsored by Dong-A ST Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.